Securing an exclusive global license for a next-generation treatment platform positions NLS Pharmaceutics at the forefront of the sleep disorder pharmaceutical market. This strategic move is likely to attract investor interest and could lead to positive stock price movement in the short term, given the potential market impact and innovation leadership it signifies.